Fulvestrant Injection shortage
Fulvestrant Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Oct 3, 2026.
Fresenius Kabi is permanently stopping its fulvestrant injection 250 mg/5 mL. Faslodex (fulvestrant) injection is still listed as available from other makers, including AstraZeneca, Hikma, Sandoz, and Northstar.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Fulvestrant Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 14, 2026Currently in shortage1 of 1 product affected.
-
Aug 14, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Fulvestrant Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Fulvestrant Injection? options further down this page.
Why is Fulvestrant Injection in shortage?
Fresenius Kabi USA has let the FDA know that they are permanently stopping the manufacturing of their specific version of fulvestrant injection — the 250 mg per 5 mL single-use vials. This isn't a temporary hold-up at the factory; they have made the decision to stop making this particular product for good.
It's worth knowing that this report only reflects what Fresenius Kabi has shared with the FDA. No specific reason was given for why they made this decision — just that they are discontinuing the manufacture of this product. Other manufacturers of fulvestrant are listed separately and are not part of this report.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Fulvestrant Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Fulvestrant Injection?
Fulvestrant injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
The single strength on this record, 250 mg per 5 mL, does not have an available source from the manufacturer who filed this report. That maker, Fresenius Kabi USA, has listed this product as being discontinued — meaning they are stopping production of it. Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for their product. This does not mean the medicine is gone from every source; other companies still make fulvestrant, and your pharmacy can look into those.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own — keep your current schedule while your pharmacy sorts out supply.
- Ask your pharmacy to source fulvestrant from another maker. The same medicine is listed from companies including Accord Healthcare, BluePoint Laboratories, Hikma, Sandoz, AstraZeneca (Faslodex), and others, though it may not be in local stock right away.
- If your exact product cannot be found, ask your prescriber or pharmacist about the best next step for you.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Fulvestrant Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Fulvestrant Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection · Intramuscular | Hikma Pharmaceuticals USA Inc. | 00143-9022-02 |
| Faslodex | FULVESTRANT 50 mg/mL | Injection · Intramuscular | AstraZeneca Pharmaceuticals LP | 00310-0720-10 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection · Intramuscular | Sandoz Inc | 00781-3532-12 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection, Solution · Intramuscular | Northstar Rx, LLC, | 16714-0070-02 |
| Fulvestrant | FULVESTRANT 250 mg/5mL | Injection · Intramuscular | Accord Healthcare Inc. | 16729-0436-30 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection, Solution · Intramuscular | Sagent Pharmaceuticals | 25021-0471-66 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection, Solution · Intramuscular | Dr.Reddy's Laboratories Inc | 43598-0262-02 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection · Intramuscular | Alembic Pharmaceuticals Inc. | 62332-0650-05 |
| Fulvestrant | FULVESTRANT 250 mg/5mL | Injection, Solution · Intramuscular | BluePoint Laboratories | 68001-0484-85 |
| Fulvestrant | FULVESTRANT 250 mg/5mL | Injection · Intramuscular | BluePoint Laboratories | 68001-0522-85 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection · Intramuscular | BluePoint Laboratories. | 68001-0626-85 |
| Fulvestrant | FULVESTRANT 50 mg/mL | Injection · Intramuscular | GLENMARK PHARMACEUTICALS INC., USA | 68462-0317-32 |
Therapeutic equivalents & pricing 24 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Fulvestrant 50 mg/mL | Hikma | 2 syringes | — | AO | FDA listed |
| Faslodex 50 mg/mL | AstraZeneca | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Sandoz | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Sandoz | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Northstar | 2 syringes | — | AO | FDA listed |
| Fulvestrant 250 mg/5mL | Accord | 2 syringes | — | AO | FDA listed |
| fulvestrant 50 mg/mL | Sagent | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Dr.Reddy's | 2 syringes | — | AO | Discontinued |
| Fulvestrant 50 mg/mL | Eugia | 2 syringes | — | — | FDA listed |
| Fulvestrant 50 mg/mL | Alembic | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Fresenius | 2 syringes | — | AO | FDA listed |
| Fulvestrant 250 mg/5mL | BluePoint | 2 syringes | — | AO | FDA listed |
| Fulvestrant 250 mg/5mL | BluePoint | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | BluePoint | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | GLENMARK | 2 syringes | — | AO | FDA listed |
| Fulvestrant 250 mg/5mL | Amneal | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Xiromed, | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Zydus | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Zydus | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Athenex | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Meitheal | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Chia | 2 syringes | — | AO | FDA listed |
| Fulvestrant 50 mg/mL | Avenacy, | 2 syringes | — | AO | FDA listed |
| Cligavyx 250 mg/5mL | Avyxa | 2 syringes | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Fulvestrant Injection — that fall in the same broad treatment class (selective estrogen receptor modulators (serms)) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Fulvestrant Injection shortage FAQs
Is Fulvestrant Injection in shortage?
Which products are affected?
When will Fulvestrant Injection be available again?
Can I still get Fulvestrant somewhere?
What should I do if I take Fulvestrant Injection?
Still have a question about the Fulvestrant Injection shortage?
Ask a pharmacist about this shortage →View Fulvestrant Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.